Rich Messmann
Chief Medical Officer Convergent Therapeutics, Inc
Rich Messmann has been an oncology drug development physician for over 25 years. Following completion of an NCI fellowship in the medical oncology, he became the Deputy Associate Director of NCI’s Developmental Therapeutics Program (DTP). He has held a variety of leadership roles in academia, large pharma and biotech and led the VISION registration of Pluvicto while at Endocyte (Novartis) where he was awarded patents related to VISION, PSMAddition and PSMAFore studies. In September 2024 he joined Convergent Therapeutics as CMO to lead clinical develop of the antibody directed CONV01-alpha.
Seminars
Wednesday 22nd July 2026
Introducing the Safety & Efficacy of CONV01-Alpha for the Treatment of Men with Advanced Prostate Cancer
4:30 pm
- Delivering a potent alpha-emitting payload directly to PSMA-expressing mCRPC cells via an antibody platform, improving tumor specificity while minimizing exposure to healthy tissues
- Avoiding key limitations of small-molecule alpha radiotherapies, including rapid renal clearance and non-specific uptake, through controlled antibody-based biodistribution
- Enabling a differentiated safety–efficacy balance in advanced prostate cancer by combining high-energy alpha radiation with precise PSMA targeting
